Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Operating Expenses: 2009-2024

Historic Operating Expenses for Myriad Genetics (MYGN) over the last 16 years, with Dec 2024 value amounting to $708.9 million.

  • Myriad Genetics' Operating Expenses fell 1.59% to $167.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 96.04%. This contributed to the annual value of $708.9 million for FY2024, which is 8.46% down from last year.
  • Per Myriad Genetics' latest filing, its Operating Expenses stood at $708.9 million for FY2024, which was down 8.46% from $774.4 million recorded in FY2023.
  • Myriad Genetics' 5-year Operating Expenses high stood at $881.1 million for FY2021, and its period low was $617.0 million during FY2022.
  • Its 3-year average for Operating Expenses is $700.1 million, with a median of $708.9 million in 2024.
  • As far as peak fluctuations go, Myriad Genetics' Operating Expenses decreased by 29.97% in 2022, and later grew by 25.51% in 2023.
  • Over the past 5 years, Myriad Genetics' Operating Expenses (Yearly) stood at $870.3 million in 2020, then reached $846.8 million in 2020, then climbed by 4.05% to $881.1 million in 2021, then dropped by 29.97% to $617.0 million in 2022, then climbed by 25.51% to $774.4 million in 2023, then dropped by 8.46% to $708.9 million in 2024.